SCHEMBL26057426

SCHEMBL26057426

CC(=O)Nc1cc2c(Nc3cccc(-c4ncc(F)cc4F)c3)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.64
▸ ERBB2 P04626 5/20 0.61
▸ KIT P10721 2/20 0.59
▸ SRC P12931 2/20 0.59
▸ ERBB3 P21860 2/20 0.59
▸ ERBB4 Q15303 2/20 0.59
▸ KDR P35968 2/20 0.59
▸ BMPR1B O00238 1/20 0.59
▸ CIT O14578 1/20 0.59
▸ MAP2K7 O14733 1/20 0.59
▸ GAK O14976 1/20 0.59
▸ EPHB6 O15197 1/20 0.59
▸ MAP3K7 O43318 1/20 0.59
▸ RIPK2 O43353 1/20 0.59
▸ STK17B O94768 1/20 0.59
▸ STK10 O94804 1/20 0.59
▸ ABL1 P00519 1/20 0.59
▸ LCK P06239 1/20 0.59
▸ FYN P06241 1/20 0.59
▸ YES1 P07947 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25218983 0.91 EGFR (0.76) EGFRERBB2KITSRCERBB3
SCHEMBL30429248 0.91 EGFR (0.76) EGFRERBB2KITSRCERBB3
SCHEMBL26056082 0.91 EGFR (0.64) EGFRERBB2KITSRCERBB3
SCHEMBL25663079 0.91 EGFR (0.58) EGFRERBB2KITSRCERBB3
SCHEMBL30429634 0.88 EGFR (0.70) EGFRERBB2KITSRCERBB3
SCHEMBL25210925 0.88 EGFR (0.70) EGFRERBB2KITSRCERBB3
SCHEMBL25663071 0.87 EGFR (0.55) EGFRERBB2KITSRCERBB3
SCHEMBL26055599 0.87 EGFR (0.79) EGFRERBB2KITSRCERBB3
SCHEMBL25663691 0.85 EGFR (0.71) EGFRERBB2KITSRCERBB3
SCHEMBL26055584 0.83 EGFR (0.73) EGFRERBB2KITSRCERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF EGFR, WEE1, WEE2 EGFR 1/4885ERBB2 5/4885KIT 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback